NCT01362803 2026-04-14
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
Clinical Trials
12 trialsNCT01089101 2026-04-13
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03190915 2026-04-13
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03871257 2026-04-13
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03962543 2026-04-08
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03975829 2026-04-02
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Active not recruiting
NCT04924608 2026-03-23
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT00924196 2026-03-20
Natural History Study of Patients With Neurofibromatosis Type I
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT05388370 2026-03-12
PASS of Paediatric Patients Initiating Selumetinib
AstraZeneca
Active not recruiting
NCT02407405 2026-03-05
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05101148 2026-02-23
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
Phase 1 Active not recruiting
NCT04590235 2026-01-30
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting